Pyrazinamide (PZA)

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Brigham and Women's Hospital, Shanghai Pulmonary Hospital, Shanghai, China

Conditions

Drug-Susceptible Pulmonary TuberculosisHIVTuberculosis, PulmonaryTuberculous Meningitis

Phase 2

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

RecruitingNCT05383742

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculous Meningitis

Start: 2023-12-07End: 2029-09-15Target: 330Updated: 2026-06-02

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis

Active, not recruitingNCT05556746

Brigham and Women's HospitalTuberculosis, Pulmonary, HIV

Start: 2023-11-24End: 2027-01-01Updated: 2026-08-05

Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis

Not yet recruitingNCT07129629

Shanghai Pulmonary Hospital, Shanghai, ChinaTuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis

Start: 2025-08-20End: 2027-12-31Target: 45Updated: 2025-08-19

Related Papers

Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis

BMJ Open2025-04-016 citations